certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-23. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Estradiol patches have an extended duration and are available for twice-weekly (3–4-day) and once-weekly (7-day) application, while gels, emulsions, and sprays are administered daily. There are two types of estradiol patches: reservoir patches, which have been described as first-generation patches, and matrix patches, which are considered to be improved second-generation patches. Reservoir patches were designed for twice-weekly application, while matrix patches have been produced for both twice-weekly and once-weekly application. Reservoir patches of estradiol (e.g., Estraderm TTS) are mostly no longer used, with most estradiol patches available today being matrix patches (e.g., Alora, Climara, Esclim, Estradot, FemPatch, Menostar, Oesclim, Vivelle, Vivelle-Dot, and Estraderm MX).
== Terminology == Although "transition matrix" is often used interchangeably with "substitution matrix" in fields other than bioinformatics, the former term is problematic in bioinformatics. With regards to nucleotide substitutions, "transition" is also used to indicate those substitutions that are between the two-ring purines (A → G and G → A) or are between the one-ring pyrimidines (C → T and T → C). Because these substitutions do not require a change in the number of rings, they occur more frequently than the other substitutions. "Transversion" is the term used to indicate the slower-rate substitutions that change a purine to a pyrimidine or vice versa (A ↔ C, A ↔ T, G ↔ C, and G ↔ T).
=== Marine Police === Since the 2008 Mumbai attacks, the Government of India took the decision to strengthen coastal security and several important decisions were taken and launched a multi-tier arrangement for protection and maritime security of the country scheme. In April 2011, Government of India sanctioned 14 coastal police stations, surveillance equipment, computer systems, furniture and jetties for the West Bengal's share of the 157.50 km coastline under the Coastal Security Scheme Phase-II.
=== Homologous recombination === Another method of cloning without the use of ligase is by DNA recombination, for example as used in the Gateway cloning system. The gene, once cloned into the cloning vector (called entry clone in this method), may be conveniently introduced into a variety of expression vectors by recombination.
Sources: en.wikipedia.org
=== Ports === Half-Life 2 was released on the Xbox console by Electronic Arts in November 2005. In 2006, Valve partnered with Taito to release Half-Life 2: Survivor, an arcade game, for the Japanese market. Valve re-released Half-Life 2 as part of the 2007 compilation The Orange Box for Windows, Xbox 360 and PlayStation 3. On May 26, 2010, Half-Life 2, Episode One and Episode Two were released for Mac OS X. In 2013, Valve ported Half-Life 2 to Linux and released a free update adding support for the Oculus Rift virtual reality headset. An Nvidia Shield Tablet-exclusive port for Android was released on May 12, 2014.
The largest amounts of estradiol are produced by the granulosa cells of the ovaries, but lesser amounts are derived from testicular and adrenal testosterone. Adrenal androgens are steroids produced by the zona reticulosa of the adrenal cortex in both sexes. The major adrenal androgens are dehydroepiandrosterone, androstenedione (which are precursors of testosterone), and dehydroepiandrosterone sulfate which is present in large amounts in the blood. Adrenal androgens contribute to the androgenic events of early puberty in females. IGF1 (insulin-like growth factor 1) rises substantially during puberty in response to rising levels of growth hormone and may be the principal mediator of the pubertal growth spurt. Leptin is a protein hormone produced by adipose tissue. Its primary target organ is the hypothalamus. The leptin level seems to provide the brain a rough indicator of adipose mass for purposes of regulation of appetite and energy metabolism. It also plays a permissive role in female puberty, which usually will not proceed until an adequate body mass has been achieved.
=== 2005–present: A new look === On 17 December 2005, the organisation obtained a new corporate identity. The previous NOS logo was in use for 36 years and featured the company's initials in lowercase, with round and obtuse angles. The O of the logo is painted red and represents "the hub of 360-degree reportage". The new logo was designed by graphic designers Lambie-Nairn, complete with new idents for its television programmes. The typeface was Gotham. Its news-gathering operations also changed, with the news departments for radio, television, and internet merging and reorganising into different sections (NOS, NOS News, NOS Sports, with NOS Events added in 2009). An announcement made by the Minister of Education in 2007 confirmed a further division of the NOS. The umbrella group Publieke Omroep, managed by the NOS was to be legally separated and renamed Nederlandse Publieke Omroep (Netherlands Public Broadcasting). The move was to ensure the NOS operated under the same conditions as its fellow broadcasting associations, as well as transferring membership of the European Broadcasting Union. In 2009, the NOS became fully independent and now has its own Board of Directors. Since 2012, the NOS has got a new style and layout and, for some programs, other titles. The biggest change is visible in the 8 o'clock NOS Journaal (traditionally the most viewed and therefore the most important news broadcast of the NOS), where they adopted a standing presentation.
The reason for using one or more housekeeping genes is to correct non-specific variation, such as the differences in the quantity and quality of RNA used, which can affect the efficiency of reverse transcription and therefore that of the whole PCR process. However, the most crucial aspect of the process is that the reference gene must be stable. The selection of these reference genes was traditionally carried out in molecular biology using qualitative or semi-quantitative studies such as the visual examination of RNA gels, northern blot densitometry or semi-quantitative PCR (PCR mimics). Now, in the genome era, it is possible to carry out a more detailed estimate for many organisms using transcriptomic technologies. However, research has shown that amplification of the majority of reference genes used in quantifying the expression of mRNA varies according to experimental conditions. It is therefore necessary to carry out an initial statistically sound methodological study in order to select the most suitable reference gene. A number of statistical algorithms have been developed that can detect which gene or genes are most suitable for use under given conditions. Those like geNORM or BestKeeper can compare pairs or geometric means for a matrix of different reference genes and tissues. The entire qPCR analysis workflow with proper error propagations is implemented in GenEx.
Donald McKain, Staff Side Coordinator, Grampian Healthcare NHS Trust. For services to Health Care. Neil McKay, Revenue Executive, Board of Inland Revenue. Stuart William McKay. For services to the de Havilland Moth Club. Evelyn Hildegard McKinley, Administrative Officer, Ministry of Defence. Norman McLean, Director, National Mentoring Consortium. For services to the Ethnic Community. Richard Dick McLean, Prison Officer, Her Majesty's Prison, Edinburgh. Carol Ross McNeilage, Nursing Auxiliary, Vale of Leven Hospital, Alexandria. For services to Health Care and to the community. Valerie Matilda McNeill. For services to the Ports Industry. Paul McStay. For services to Association Football. Joseph Henry McWhirter. For services to the community and to the Post Office. Ivy Florence Medley. For services to the community in St Lawrence, Essex. Jeremiah Joseph Mee. For services to the Sick Dentist Scheme. David Klemman Meeker. For services to the National Film and Television Archive. Bridget Anne Meyer, Higher Executive Officer, Commonwealth War Graves Commission. Rolf Meyer. For services to the community in Brixham, Devon. Donald John Milburn. For services to the Police and to the community. Evelyn May Miller, Administrative Officer, Ministry of Defence. Nicholas Charles Miller. For services to People with Alcohol Problems. Sheila Denise Miller. For services to the British Tourist Authority. Squadron Leader Raymond Mills. For services to the community in Cambridgeshire. Ena Montgomery. For services to the community in Chorley, Lancashire. Robert Joseph Montgomery.
Sources: en.wikipedia.org
=== Strategies for toxicity prevention === Understanding the mechanisms behind the toxicity of gliotoxin can open new possibilities for the use of gliotoxin therapeutically or as a diagnostic test for some conditions. One potential strategy that has been explored to reduce the toxicity of the fungi that produce gliotoxin is to target the gli gene cluster that controls the expression of gliotoxin protein. The disulfide bridge of gliotoxin is crucial to its toxicity, so it is theorized that the tailoring of enzymes to prevent the disulfide bridge closure by interfering with GliT or by catalyzing another reaction to block the sulfur residues may be beneficial in reducing the toxicity of those fungi. Another potential strategy is the targeting of the transcriptional activator GliZ, as deletion of the GliZ resulted in abrogated gliotoxin biosynthesis. This leads to the possible targeting of GliZ itself rather than any gene-based methodology to prevent it from binding to the gli gene cluster and activate transcription of the genes required for gliotoxin biosynthesis. One possible strategy for disrupting the regulation of gliotoxin transport is depleting the amount of GipA in the cell. GipA is a transcriptional regulator for the expression of the GliA transporter protein, which is required for gliotoxin secretion. These biosynthetic strategies for reducing the toxicity of pathogenic fungal strains that produce gliotoxin are still in their early stages of exploration but could provide novel methodologies for the adoption of therapeutic uses for gliotoxin.
== Trends in the chart of nuclides == The trends in this section refer to the following chart, which shows Z increasing to the right and N increasing downward, a 90° clockwise rotation of the above landscape-orientation charts.
=== DNA repair === RECQL4 has a crucial role in DNA end resection that is the initial step required for homologous recombination (HR)-dependent double-strand break repair. When RECQL4 is depleted, HR-mediated repair and 5' end resection are severely reduced in vivo. RECQL4 also appears to be necessary for other forms of DNA repair including non-homologous end joining, nucleotide excision repair and base excision repair. The association of deficient RECQL4-mediated DNA repair with accelerated aging is consistent with the DNA damage theory of aging.
The genealogy of lifting can be traced back to the beginning of recorded history where humanity's fascination with physical abilities can be found among numerous ancient writings. In many prehistoric tribes, they would have a big rock they would try to lift, and the first one to lift it would inscribe their name into the stone. Such rocks have been found in Greek and Scottish castles. Progressive resistance training dates back at least to Ancient Greece, when legend has it that wrestler Milo of Croton trained by carrying a newborn calf on his back every day until it was fully grown. Another Greek, the physician Galen, described strength training exercises using the halteres (an early form of dumbbell) in the 2nd century. Ancient Greek sculptures also depict lifting feats. The weights were generally stones, but later gave way to dumbbells. The dumbbell was joined by the barbell in the later half of the 19th century. Early barbells had hollow globes that could be filled with sand or lead shot, but by the end of the century these were replaced by the plate-loading barbell commonly used today. Weightlifting was first introduced in the Olympics in the 1896 Athens Olympic Games as a part of track and field, and was officially recognized as its own event in 1914. The 1960s saw the gradual introduction of exercise machines into the still-rare strength training gyms of the time. Weight training became increasingly popular in the 1970s, following the release of the bodybuilding movie Pumping Iron, and the subsequent popularity of Arnold Schwarzenegger.
This settlement, boycotted by the PF and rejected internationally, led to multiracial elections and Rhodesia's reconstitution under majority rule as Zimbabwe Rhodesia in June 1979. Muzorewa, the electoral victor, took office as the country's first black prime minister at the head of a coalition cabinet comprising 12 blacks and five whites, including Smith as minister without portfolio. Dismissing Muzorewa as a "neocolonial puppet", ZANLA and ZIPRA continued their armed struggle until December 1979, when Whitehall, Salisbury and the Patriotic Front settled at Lancaster House. Muzorewa's government revoked UDI, thereby ending the country's claim to be independent after 14 years, and dissolved itself. The UK suspended the constitution and vested full executive and legislative powers in a new Governor, Lord Soames, who oversaw a ceasefire and fresh elections during February and March 1980. These were won by ZANU, whose leader Robert Mugabe became Prime Minister when the UK granted independence to Zimbabwe as a republic within the Commonwealth in April 1980. African nationalist politicians continued to cite their opposition to the UDI as a means of legitimising their rule of Zimbabwe into the 21st century. Since it was issued, the UDI has been recounted in scholarly literature, autobiographies of those involved in its creation, and works of fiction.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.